{"meta":{"query_hash":"4468135ef0ab","filters":{"venue":"Current Cancer Drug Targets"},"cohort_total":37,"direct_labels_cover":0,"predictions_cover":37,"exported":37,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/4468135ef0ab","api":"https://metacan.xera.ac/api/v1/cohort?venue=Current+Cancer+Drug+Targets"},"results":[{"id":"W131285836","doi":"10.2174/156800907780058844","title":"Oncolytic Viruses: Whats Next?","year":2007,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Canada","funders":"","keywords":"Oncolytic virus; Exploit; Cancer; Biology; Computational biology; Virus; Computer science; Virology; Computer security; Genetics","score_opus":0.1284561124885577,"score_gpt":0.4518016595399557,"score_spread":0.323345547051398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W131285836","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015208485,0.9893049,0.00048145824,0.006259436,0.0018163375,0.000009087608,0.000014077431,0.000019686375,0.0019428774],"genre_scores_gemma":[0.0011449086,0.9925114,0.0005895413,0.0024645939,0.0013493872,0.000011457256,0.000014597299,0.0000056312174,0.0019084313],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996086,0.000099133955,0.000035936482,0.00005437576,0.00015957297,0.000042381336],"domain_scores_gemma":[0.9993789,0.00026740402,0.000058409492,0.000027003602,0.00016663581,0.00010162286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018589328,0.0010556731,0.0015829416,0.0011952856,0.0006369116,0.0023524764,0.0010885358,0.0029287557,0.0037973947],"category_scores_gemma":[0.0013420653,0.00045844045,0.00048123326,0.001425712,0.0015398542,0.008083687,0.0008560683,0.004910797,0.003931161],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000110668094,0.00009032226,0.00027593787,0.005106899,0.000035765195,0.00031675873,0.00017990568,0.00036280966,0.0024234331,0.02421044,0.06495192,0.9019351],"study_design_scores_gemma":[0.000016523589,0.00008544489,0.00019997063,0.00142454,0.000020319187,0.00080852205,0.00020971538,0.000092024515,0.0005406389,0.0096224835,0.986961,0.00001882457],"about_ca_topic_score_codex":0.0013846983,"about_ca_topic_score_gemma":0.0026235401,"teacher_disagreement_score":0.0037973947,"about_ca_system_score_codex":0.00133293,"about_ca_system_score_gemma":0.0015445416,"threshold_uncertainty_score":0.012703538},"labels":[],"label_agreement":null},{"id":"W1984087096","doi":"10.2174/156800907780058853","title":"Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus","year":2007,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Georgetown University; University of Pennsylvania","keywords":"Oncolytic virus; Medicine; Tolerability; Adverse effect; Desensitization (medicine); Regimen; Dosing; Toxicity; Pharmacology; Bolus (digestion); Phases of clinical research; Newcastle disease; Clinical trial; Internal medicine; Oncology; Virus; Cancer; Immunology; Receptor","score_opus":0.24429777598706143,"score_gpt":0.5522660217318367,"score_spread":0.30796824574477527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984087096","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768684,0.0053636627,0.004033223,0.001071944,0.00017522777,0.0032362808,0.0014967179,0.0001776184,0.007576932],"genre_scores_gemma":[0.98097825,0.0039269114,0.0037303623,0.0013190203,0.00018594737,0.0016148841,0.0043817717,0.00005903224,0.0038038972],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992374,0.00038002818,0.000028526098,0.00012911129,0.0001038545,0.000121095334],"domain_scores_gemma":[0.999008,0.00029440137,0.00013669099,0.000116113486,0.00014351317,0.00030132776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023764533,0.0014139095,0.0013636118,0.00018666593,0.0006425933,0.00077235524,0.0007207061,0.0009764624,0.0019449133],"category_scores_gemma":[0.0017168926,0.0004022384,0.000674616,0.0002617722,0.0007415144,0.0006317385,0.00034031397,0.002357771,0.000661345],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10247433,0.11782703,0.025381397,0.0011703019,0.0013160624,0.0014016307,0.0022557457,0.009193517,0.18726112,0.0008832457,0.029253908,0.5215817],"study_design_scores_gemma":[0.06848326,0.8359825,0.039933126,0.00008267189,0.0004229671,0.0016244479,0.0001625586,0.002341519,0.02444832,0.00041376866,0.02604183,0.00006308496],"about_ca_topic_score_codex":0.002913494,"about_ca_topic_score_gemma":0.003839732,"teacher_disagreement_score":0.002913494,"about_ca_system_score_codex":0.001131849,"about_ca_system_score_gemma":0.0014300206,"threshold_uncertainty_score":0.012568057},"labels":[],"label_agreement":null},{"id":"W1988669425","doi":"10.2174/156800912802429337","title":"Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma","year":2012,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"CD44; Integrin; Extracellular matrix; Cell biology; Cell adhesion molecule; Cell adhesion; Fibronectin; Chemistry; Laminin; Adhesion; Cancer research; Biology; Cell; Biochemistry","score_opus":0.11710704615758474,"score_gpt":0.4100367581634505,"score_spread":0.2929297120058657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988669425","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007321391,0.9869322,0.0011431259,0.00085791823,0.00038285358,0.000035784553,0.000036633857,0.00003863591,0.0032515365],"genre_scores_gemma":[0.03540779,0.9590381,0.0016881578,0.0008599839,0.00035748034,0.0000494164,0.000090980524,0.000006632714,0.0025015294],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999207,0.000018044191,0.0000067536066,0.000009285705,0.000030166158,0.000015030117],"domain_scores_gemma":[0.9999702,0.000008677742,0.000008371775,0.0000010034463,0.0000070870733,0.00000476687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025740615,0.0003509742,0.0005425256,0.00063485565,0.00015737247,0.0005158195,0.00035491088,0.0007379705,0.0012056552],"category_scores_gemma":[0.0001289889,0.00012472578,0.0003153909,0.00046122455,0.00016083862,0.0004322137,0.000309233,0.0012080893,0.00047381522],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047048897,0.00060985144,0.00051809195,0.012152623,0.0002248375,0.00208177,0.00022507843,0.0018242352,0.2138868,0.0124331955,0.018498717,0.7370743],"study_design_scores_gemma":[0.0002455611,0.0026057172,0.0033899923,0.0019001025,0.000349402,0.004846384,0.00011917146,0.0012935959,0.04888801,0.0041035637,0.93220854,0.00005014639],"about_ca_topic_score_codex":0.00030190538,"about_ca_topic_score_gemma":0.00074209296,"teacher_disagreement_score":0.0012056552,"about_ca_system_score_codex":0.00038929793,"about_ca_system_score_gemma":0.00021694787,"threshold_uncertainty_score":0.004033327},"labels":[],"label_agreement":null},{"id":"W1990604167","doi":"10.2174/156800908785699306","title":"Epigenetic Aberrations and Targeted Epigenetic Therapy of Esophageal Cancer","year":2008,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Royal University Hospital","funders":"","keywords":"Epigenetics; Malignancy; Esophageal cancer; Biology; Esophagus; Disease; Epigenetic therapy; Cancer; Cancer research; Carcinogenesis; Somatic evolution in cancer; Bioinformatics; Carcinoma; Medicine; Genetics; Pathology; Internal medicine; Gene; DNA methylation; Gene expression","score_opus":0.04657069195341299,"score_gpt":0.36571571210259707,"score_spread":0.31914502014918406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990604167","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004437428,0.9973495,0.00029704103,0.00030587273,0.00019472367,0.000006269024,0.000009910834,0.000010139682,0.0013828086],"genre_scores_gemma":[0.0017838038,0.9959656,0.00033286377,0.00025512622,0.00014248,0.000009568149,0.000023330487,0.000001743204,0.0014853228],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989533,0.00001971883,0.000010722343,0.000016806134,0.000046139776,0.000011220363],"domain_scores_gemma":[0.99993587,0.000022578803,0.000011170966,0.0000028201937,0.00001920228,0.000008360877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034855725,0.0006245376,0.00105845,0.0011416483,0.00021759733,0.000449843,0.00074165536,0.00097004947,0.0017819011],"category_scores_gemma":[0.00028727503,0.00017741953,0.00031858488,0.0011206601,0.00030371608,0.00072133244,0.00040718168,0.0011963561,0.0014674608],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000953461,0.000100325364,0.0001984543,0.0045825676,0.0000691482,0.000691216,0.000049715694,0.0004961784,0.006616709,0.0026748457,0.020982154,0.9634434],"study_design_scores_gemma":[0.000047706904,0.00022523169,0.0014660131,0.0009358097,0.00007461986,0.0051602535,0.000050517385,0.00022885298,0.0030344317,0.0018129452,0.9869466,0.000017053204],"about_ca_topic_score_codex":0.0006980557,"about_ca_topic_score_gemma":0.0018116479,"teacher_disagreement_score":0.0017819011,"about_ca_system_score_codex":0.0005210949,"about_ca_system_score_gemma":0.0004196273,"threshold_uncertainty_score":0.0059610605},"labels":[],"label_agreement":null},{"id":"W1996963479","doi":"10.2174/156800912799277511","title":"The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases","year":2012,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Canada Research Chairs","keywords":"Medicine; Blood–brain barrier; Chemotherapy; Brain tumor; Brain metastasis; Radiation therapy; Oncology; Brain cancer; Cancer; Internal medicine; Pathology; Central nervous system; Metastasis","score_opus":0.05824059173052305,"score_gpt":0.3778907565616442,"score_spread":0.3196501648311212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996963479","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00057199004,0.9957963,0.00037264515,0.0017641635,0.00035060348,0.0000038613816,0.000008790263,0.000008029258,0.0011235757],"genre_scores_gemma":[0.005988468,0.9915609,0.0003709036,0.00070376013,0.0007059165,0.0000067206174,0.000011318607,0.000003575521,0.0006483933],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99965274,0.000102051185,0.000044494296,0.000056668072,0.00010905237,0.000035055415],"domain_scores_gemma":[0.99935573,0.00030731867,0.00010647067,0.000008463301,0.00018471213,0.000037327056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006030891,0.00039084672,0.0006141704,0.0010032878,0.00027796524,0.0013080456,0.00040912125,0.001038125,0.0013391696],"category_scores_gemma":[0.0009890844,0.000105106345,0.0003688652,0.00075787655,0.0008279332,0.0015072526,0.0005667131,0.002037053,0.0006425618],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020457503,0.000085195585,0.001288165,0.017557276,0.00012869401,0.0012113291,0.00032194637,0.0008232973,0.011406628,0.018695857,0.03622335,0.91205364],"study_design_scores_gemma":[0.000014575192,0.0004613974,0.004228069,0.0042456356,0.00020465055,0.008157938,0.00030622643,0.00045849584,0.005856086,0.0068305256,0.9691804,0.000056063825],"about_ca_topic_score_codex":0.0011537343,"about_ca_topic_score_gemma":0.0013553114,"teacher_disagreement_score":0.0013391696,"about_ca_system_score_codex":0.0010436678,"about_ca_system_score_gemma":0.001033943,"threshold_uncertainty_score":0.007572353},"labels":[],"label_agreement":null},{"id":"W2003470917","doi":"10.2174/156800908786733450","title":"Anti-Angiogenic Targets in the Treatment of Advanced Renal Cell Carcinoma","year":2008,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Health Canada; Memorial Sloan-Kettering Cancer Center","keywords":"Pazopanib; Temsirolimus; Sunitinib; Axitinib; Sorafenib; Everolimus; Medicine; Vascular endothelial growth factor; Cancer research; Renal cell carcinoma; Bevacizumab; Platelet-derived growth factor receptor; Angiogenesis; PI3K/AKT/mTOR pathway; Tyrosine-kinase inhibitor; Growth factor; Pharmacology; Internal medicine; Cancer; Biology; Signal transduction; VEGF receptors; Discovery and development of mTOR inhibitors; Receptor; Chemotherapy; Hepatocellular carcinoma","score_opus":0.05341450169617008,"score_gpt":0.340254233950875,"score_spread":0.28683973225470494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003470917","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003516459,0.9967655,0.00015455674,0.00020323289,0.00015227206,0.000010088443,0.000015717724,0.0000110346855,0.0023360194],"genre_scores_gemma":[0.0012421181,0.9967759,0.00029281894,0.00020007443,0.0001270703,0.000009375524,0.000033810764,0.0000015122081,0.0013172129],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998734,0.00002066699,0.000012838276,0.00001572416,0.00006500209,0.000012360859],"domain_scores_gemma":[0.9998934,0.000035492303,0.000019932706,0.0000030021765,0.000033270277,0.0000148921645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039259245,0.00057175994,0.0010477873,0.0019252037,0.00023621935,0.00057141425,0.00057234196,0.00065948797,0.0031087645],"category_scores_gemma":[0.0002769497,0.0001949486,0.00031641638,0.0018601649,0.0002683664,0.00072260015,0.00032036853,0.0011868909,0.0026005532],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009081895,0.00015310718,0.00016999673,0.006175895,0.000067568326,0.00032998438,0.00004535211,0.00037799284,0.0032866907,0.0017492885,0.021323072,0.96623015],"study_design_scores_gemma":[0.000055314144,0.000204083,0.0014413156,0.0014221681,0.00008015224,0.0018905732,0.000044838267,0.0001313932,0.000971281,0.0010273415,0.99271846,0.000013135843],"about_ca_topic_score_codex":0.0009691391,"about_ca_topic_score_gemma":0.0024569212,"teacher_disagreement_score":0.0031087645,"about_ca_system_score_codex":0.00048559118,"about_ca_system_score_gemma":0.0005881924,"threshold_uncertainty_score":0.010399878},"labels":[],"label_agreement":null},{"id":"W2010349266","doi":"10.2174/156800907780058862","title":"From ONYX-015 to Armed Vaccinia Viruses: The Education and Evolution of Oncolytic Virus Development","year":2007,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jennerex Biotherapeutics (Canada)","funders":"","keywords":"Vaccinia; Oncolytic virus; Virology; Virus; Biology; Medicine; Genetics","score_opus":0.05896900290161484,"score_gpt":0.41964664024537085,"score_spread":0.360677637343756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010349266","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19585289,0.5259261,0.11873642,0.0767032,0.005283622,0.00022758952,0.000244724,0.00054907927,0.076476425],"genre_scores_gemma":[0.51452714,0.34518573,0.08864762,0.010889175,0.0015584229,0.00012591261,0.00030085185,0.00025143274,0.03851369],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995459,0.00017174582,0.000029496652,0.000080549245,0.000107107015,0.00006518463],"domain_scores_gemma":[0.9994142,0.0002063219,0.00007540441,0.00004802719,0.00010102655,0.00015496937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029941439,0.00036601615,0.0002396327,0.00043075782,0.00035049673,0.0014188964,0.0004427451,0.0008334301,0.0016321237],"category_scores_gemma":[0.0016305923,0.00025013022,0.00021092266,0.00034202042,0.0017017527,0.0023385144,0.001412261,0.002764463,0.0004519827],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044351417,0.00032083277,0.0021862355,0.0012294569,0.00003862245,0.00032174218,0.0019836857,0.002859939,0.07552331,0.22035903,0.014892576,0.67984116],"study_design_scores_gemma":[0.00011877608,0.0009421879,0.0019159563,0.000803645,0.000037731537,0.00064637966,0.0005946372,0.0025449109,0.0880686,0.044505723,0.8597587,0.000062771775],"about_ca_topic_score_codex":0.0012701204,"about_ca_topic_score_gemma":0.0013099893,"teacher_disagreement_score":0.0029941439,"about_ca_system_score_codex":0.001976553,"about_ca_system_score_gemma":0.0014655113,"threshold_uncertainty_score":0.015834749},"labels":[],"label_agreement":null},{"id":"W2011022421","doi":"10.2174/156800905774574020","title":"Cellular and Molecular Surrogate Markers to Monitor Targeted and Non- Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose","year":2005,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Pharmacology; Drug; Cancer; Drug development; Dosing; Pharmacokinetics; Pharmacodynamics; Cancer research; Internal medicine","score_opus":0.019165005628215513,"score_gpt":0.3107667388099772,"score_spread":0.2916017331817617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011022421","genre_codex":"methods","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28904283,0.0928246,0.57972425,0.0019352013,0.0012392855,0.0012459467,0.004806937,0.0015786943,0.027602265],"genre_scores_gemma":[0.6923618,0.018701175,0.27214712,0.0010390263,0.00039633847,0.0014701576,0.0031391415,0.00020108435,0.0105441045],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99718225,0.0012535402,0.00025605859,0.00023717529,0.0009421239,0.00012888998],"domain_scores_gemma":[0.9984181,0.00043380816,0.0005051031,0.00019817355,0.00032979212,0.00011495073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021421297,0.0008072824,0.00075310306,0.001417553,0.00025255728,0.001317614,0.00045254227,0.0010679949,0.002162713],"category_scores_gemma":[0.0015147199,0.00028692847,0.0004697481,0.0009893803,0.0005710818,0.0009067609,0.00042292775,0.0017381782,0.0009314013],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052781624,0.00034453344,0.0044644233,0.00077309064,0.00006723543,0.00009639374,0.00007249944,0.0030518179,0.93398464,0.00441388,0.0010219599,0.051181693],"study_design_scores_gemma":[0.000044424716,0.0021702682,0.0074236905,0.000111775465,0.00008220251,0.0005134062,0.00009875314,0.007980672,0.9553118,0.001664893,0.024548193,0.000049936953],"about_ca_topic_score_codex":0.00027581822,"about_ca_topic_score_gemma":0.0005427248,"teacher_disagreement_score":0.002162713,"about_ca_system_score_codex":0.0006153088,"about_ca_system_score_gemma":0.00046274293,"threshold_uncertainty_score":0.011328816},"labels":[],"label_agreement":null},{"id":"W2027556747","doi":"10.2174/156800910791859452","title":"Antisense Treatment in Human Prostate Cancer and Melanoma","year":2010,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Victoria Hospital; Western University","funders":"Canadian Institutes of Health Research; Francis Crick Institute","keywords":"Prostate cancer; Antisense therapy; Clusterin; Cancer; Cancer research; RNA; Medicine; Prostate; Biology; Internal medicine; Gene; Apoptosis; Locked nucleic acid; Genetics","score_opus":0.055797279390798975,"score_gpt":0.4177648667764648,"score_spread":0.3619675873856658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027556747","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019514468,0.99599,0.00022196774,0.00014767777,0.00023283681,0.000011693302,0.00001806795,0.000011577104,0.0031711014],"genre_scores_gemma":[0.0014731268,0.9946956,0.00030582288,0.00031762297,0.00014286206,0.000017108945,0.000044938497,0.0000032309065,0.0029997267],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998634,0.000024638797,0.000013406809,0.000026900943,0.000059690778,0.000011970533],"domain_scores_gemma":[0.9999231,0.00002935392,0.000013791469,0.0000037622997,0.000020654421,0.00000933822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003586125,0.0008731696,0.0010697785,0.0018013228,0.00032945315,0.000648597,0.0005390101,0.000904492,0.0034835602],"category_scores_gemma":[0.00026928962,0.0002719598,0.0003830894,0.0013512926,0.00041756986,0.00075272884,0.0004893281,0.0013692713,0.0029847014],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000727861,0.000109092965,0.00013000633,0.008761024,0.00005482255,0.00036296694,0.0000944021,0.00043201953,0.00869644,0.0061138156,0.034661364,0.9405113],"study_design_scores_gemma":[0.00002069004,0.000111191286,0.0005443611,0.0011356513,0.00003235268,0.0015099959,0.00003181139,0.00005979381,0.0015579989,0.0014121922,0.9935702,0.000013634054],"about_ca_topic_score_codex":0.0015377033,"about_ca_topic_score_gemma":0.0035606422,"teacher_disagreement_score":0.0034835602,"about_ca_system_score_codex":0.0006045783,"about_ca_system_score_gemma":0.00060274836,"threshold_uncertainty_score":0.011653662},"labels":[],"label_agreement":null},{"id":"W2028643899","doi":"10.2174/1568009043481542","title":"Transforming Growth Factor-β Superfamily: Evaluation as Breast Cancer Biomarkers and Preventive Agents","year":2004,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"TGF-β signaling in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"SMAD; Transforming growth factor; Smad2 Protein; Signal transduction; Growth differentiation factor; Breast cancer; Cancer research; Receptor; Biology; Transforming growth factor beta; Cancer; Cell biology; Bone morphogenetic protein; Biochemistry; Genetics; Gene","score_opus":0.04984810400057648,"score_gpt":0.38378748875309443,"score_spread":0.33393938475251794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028643899","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00056307047,0.9960806,0.00018149136,0.00022093087,0.00021322306,0.000007369772,0.000018674147,0.000008360234,0.0027062744],"genre_scores_gemma":[0.0018810919,0.9946266,0.00042735002,0.00019108695,0.00018066714,0.000010707507,0.00004430019,0.0000019112902,0.0026363246],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998996,0.000015693697,0.000011803022,0.000016736452,0.000046207177,0.000009889766],"domain_scores_gemma":[0.99983394,0.000049954917,0.00002486159,0.0000055216346,0.000058909405,0.000026765652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005025829,0.0005569655,0.00080423994,0.0013893335,0.00017741512,0.00066873553,0.00054290274,0.00069401046,0.0035004949],"category_scores_gemma":[0.00038270012,0.00014799616,0.0002092872,0.0016582278,0.00023834984,0.00078604714,0.00029979178,0.000847861,0.0030723172],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012176276,0.000085667125,0.00016966363,0.0030199583,0.000029617233,0.00020955438,0.000028649394,0.00016955832,0.0040894374,0.0016991843,0.011489819,0.9788871],"study_design_scores_gemma":[0.000046446217,0.00030360135,0.001142814,0.0009118544,0.00005977484,0.0017511236,0.000047045505,0.000105240404,0.0025005299,0.0008785822,0.992241,0.000011937424],"about_ca_topic_score_codex":0.0005535885,"about_ca_topic_score_gemma":0.00116208,"teacher_disagreement_score":0.0035004949,"about_ca_system_score_codex":0.00044666376,"about_ca_system_score_gemma":0.0006094493,"threshold_uncertainty_score":0.011710286},"labels":[],"label_agreement":null},{"id":"W2032167680","doi":"10.2174/15680096113139990076","title":"P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives","year":2013,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":392,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"P-glycoprotein; Multiple drug resistance; Efflux; Pharmacology; Drug resistance; Cancer cell; Chemotherapy; Drug; Cancer; Medicine; Cancer research; Biology; Internal medicine; Biochemistry","score_opus":0.042917764602676295,"score_gpt":0.35926490706292274,"score_spread":0.3163471424602464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032167680","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013780023,0.9986766,0.00012663666,0.00025701767,0.000107450025,0.0000045305414,0.000010481056,0.000008044937,0.00067143876],"genre_scores_gemma":[0.00050049706,0.9988625,0.0001642402,0.00011954999,0.000097426564,0.0000048665083,0.00001471373,0.0000010038098,0.00023523947],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99982697,0.000032684176,0.000025001224,0.000031019983,0.000066257046,0.00001811847],"domain_scores_gemma":[0.99968684,0.00013430463,0.000045470537,0.000009355024,0.00009140473,0.000032538563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005980506,0.0008016084,0.0015601491,0.0020486095,0.00027833888,0.0010258607,0.0008562343,0.0010927421,0.004204058],"category_scores_gemma":[0.0005113193,0.00024551223,0.00057524105,0.0024674137,0.0005145302,0.0015144878,0.0006065273,0.0020059224,0.0021631627],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007623032,0.00014698278,0.00014250341,0.013518194,0.000066198234,0.00024087355,0.000050947503,0.00032547544,0.0026953388,0.0025229962,0.018300444,0.9619138],"study_design_scores_gemma":[0.000036380938,0.00028143602,0.0010074595,0.0034240442,0.00018820986,0.0020580052,0.00007481689,0.00022080228,0.0008819364,0.0019934482,0.9898009,0.000032649812],"about_ca_topic_score_codex":0.0007159564,"about_ca_topic_score_gemma":0.0015831777,"teacher_disagreement_score":0.004204058,"about_ca_system_score_codex":0.0005495132,"about_ca_system_score_gemma":0.00089174166,"threshold_uncertainty_score":0.014064014},"labels":[],"label_agreement":null},{"id":"W2032199025","doi":"10.2174/1568009023333926","title":"Mutant Epidermal Growth Factor Receptors as Targets for Cancer Therapy","year":2002,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Receptor; Epidermal growth factor receptor; Epidermal growth factor; Cancer research; Extracellular; Biology; Tyrosine kinase; Epitope; Cancer; Receptor tyrosine kinase; Cancer cell; Mutant; Growth factor receptor; Mutation; Growth factor receptor inhibitor; Antibody; Cell biology; Immunology; Biochemistry; Genetics; Gene","score_opus":0.1673419595737975,"score_gpt":0.45933838070023336,"score_spread":0.29199642112643587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032199025","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025817787,0.99615365,0.00023466014,0.0003415685,0.00025536717,0.000009021206,0.000012619675,0.0000126308005,0.0027222335],"genre_scores_gemma":[0.0011912232,0.9955896,0.00033258394,0.00034526328,0.00015703695,0.000012454561,0.00002723101,0.0000023143575,0.002342205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99977463,0.000045736702,0.000018730072,0.000028282213,0.00011318626,0.000019403464],"domain_scores_gemma":[0.9998739,0.000052104104,0.00001533394,0.0000057815814,0.000036532703,0.0000163583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006299525,0.00071725284,0.0012889735,0.0020252224,0.0002791617,0.0008301669,0.00088535936,0.0011918321,0.004005027],"category_scores_gemma":[0.00040261168,0.00022989171,0.00039314266,0.001745811,0.00046274607,0.0011856717,0.0004508458,0.0016696857,0.003575687],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012977987,0.0001691361,0.0001559286,0.0068298858,0.0000686452,0.0004931891,0.00008326564,0.00059250236,0.0055548977,0.0080571165,0.04197028,0.93589526],"study_design_scores_gemma":[0.00003933404,0.00010186316,0.00037679778,0.0008640452,0.000036168964,0.001297172,0.000031855805,0.00009203702,0.0008212007,0.0020249314,0.99430484,0.000009677078],"about_ca_topic_score_codex":0.0006383507,"about_ca_topic_score_gemma":0.001320694,"teacher_disagreement_score":0.004005027,"about_ca_system_score_codex":0.0008157654,"about_ca_system_score_gemma":0.00055996655,"threshold_uncertainty_score":0.013398111},"labels":[],"label_agreement":null},{"id":"W2048425980","doi":"10.2174/1568009043481551","title":"Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications","year":2004,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Signal transduction; Biology; Cancer research; Cancer cell; Apoptosis; Cell biology; Programmed cell death; Cancer; Kinase; Cell signaling; Genetics","score_opus":0.03671337346671952,"score_gpt":0.327231160591954,"score_spread":0.29051778712523446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048425980","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00181697,0.9942735,0.00046711153,0.00058926473,0.00024738908,0.000008791446,0.00003643265,0.000015254291,0.002545308],"genre_scores_gemma":[0.014582285,0.98201007,0.00066521973,0.00042491072,0.00035185006,0.000020980362,0.00008074927,0.000003529867,0.0018603976],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989927,0.000021776608,0.000011484837,0.000016054553,0.000031388743,0.000020135863],"domain_scores_gemma":[0.99992955,0.000022209117,0.000013296113,0.0000025239858,0.000024119956,0.0000083131345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023941368,0.0003255882,0.0004916893,0.0006767432,0.00016456303,0.00054729613,0.00035292094,0.0005985013,0.0017798151],"category_scores_gemma":[0.000196739,0.0000941494,0.00026220706,0.00059280626,0.00020562063,0.0004985886,0.00024810043,0.0009937055,0.00055332365],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029960932,0.000248075,0.0006402799,0.010544253,0.00007900964,0.0008295615,0.00017766372,0.0009112714,0.049354002,0.013170321,0.019038137,0.9047079],"study_design_scores_gemma":[0.000059993028,0.0009032948,0.0038584704,0.0015626337,0.00015396315,0.0053687957,0.00019457881,0.00057366723,0.021779269,0.0071539413,0.9583414,0.000050032253],"about_ca_topic_score_codex":0.00030273636,"about_ca_topic_score_gemma":0.00066549523,"teacher_disagreement_score":0.0017798151,"about_ca_system_score_codex":0.0004243125,"about_ca_system_score_gemma":0.00032477718,"threshold_uncertainty_score":0.005954087},"labels":[],"label_agreement":null},{"id":"W2052792754","doi":"10.2174/1568009043332989","title":"Novel Approaches for Targeted Cancer Therapy","year":2004,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"National Institute of Neurological Disorders and Stroke; Canadian Institutes of Health Research","keywords":"Cancer; Cancer therapy; Targeted therapy; Medicine; Internal medicine","score_opus":0.18711714940376617,"score_gpt":0.41402475167517727,"score_spread":0.2269076022714111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052792754","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009507061,0.9566936,0.010774996,0.0024292718,0.0012928041,0.00007780058,0.000053767475,0.00009694755,0.027630152],"genre_scores_gemma":[0.007981331,0.9648953,0.0074273823,0.0019429958,0.00077190506,0.00015751742,0.000108331915,0.000015652362,0.016699566],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99970055,0.000060507922,0.000015517195,0.000049103444,0.00014267156,0.00003175095],"domain_scores_gemma":[0.99991405,0.000028637796,0.0000115104685,0.000009277933,0.000023990104,0.000012506572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065213995,0.0008312711,0.00093576335,0.0012683179,0.00035077118,0.0012683088,0.0010186693,0.0013169873,0.0075515034],"category_scores_gemma":[0.0003125881,0.00027031777,0.00053036923,0.00084192405,0.0009201891,0.001506274,0.0008817145,0.0027276676,0.0049354276],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009262946,0.0002480773,0.00017227608,0.0062906183,0.000099095916,0.00076345523,0.00021132822,0.0010626275,0.024491154,0.085208096,0.043657403,0.83770317],"study_design_scores_gemma":[0.000024664698,0.00007988451,0.00014191522,0.000469562,0.000021033833,0.0010930238,0.00003056875,0.00018546447,0.0027268766,0.00891887,0.9862955,0.000012674788],"about_ca_topic_score_codex":0.00045324143,"about_ca_topic_score_gemma":0.0007847426,"teacher_disagreement_score":0.0075515034,"about_ca_system_score_codex":0.0010383021,"about_ca_system_score_gemma":0.000734337,"threshold_uncertainty_score":0.025262237},"labels":[],"label_agreement":null},{"id":"W2058472600","doi":"10.2174/1568009054629672","title":"Molecular Targets from VHL Studies into the Oxygen-Sensing Pathway","year":2005,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"National Cancer Institute; Terry Fox Foundation","keywords":"Ubiquitin ligase; Carcinogenesis; Hypoxia-inducible factors; Biology; Cancer research; Ubiquitin; Transcription factor; Vascular endothelial growth factor; Angiogenesis; Tumor suppressor gene; HIF1A; Cell biology; Cancer; Gene; Genetics; VEGF receptors","score_opus":0.039265318781170046,"score_gpt":0.3508890844591312,"score_spread":0.31162376567796113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058472600","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031470205,0.9953897,0.0003849652,0.000558792,0.00048721975,0.000005295392,0.000013886244,0.000016988586,0.0028284423],"genre_scores_gemma":[0.0017185784,0.9936904,0.00041508942,0.0004700223,0.00032156712,0.00000792039,0.000032651384,0.0000028429586,0.003340969],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999261,0.000010932792,0.000007471133,0.00001580722,0.000030968018,0.00000870711],"domain_scores_gemma":[0.9999082,0.000026994981,0.000011655015,0.0000051400093,0.0000304243,0.000017624381],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031118642,0.00082043034,0.00092805503,0.0015180497,0.00026741653,0.00083974394,0.0007605405,0.0009387809,0.0027936937],"category_scores_gemma":[0.00031588713,0.00020044913,0.00023684315,0.0013585511,0.00049011706,0.0014013462,0.0005617413,0.0014714439,0.0034915227],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001267789,0.00010968953,0.00021148614,0.0064743157,0.000049224105,0.0009582564,0.0000917847,0.00075806124,0.013205286,0.010803943,0.05018827,0.917023],"study_design_scores_gemma":[0.000015067401,0.00004559287,0.00029368422,0.0005191244,0.000020671889,0.0012425891,0.000030343836,0.0000749451,0.001369012,0.0023988264,0.9939813,0.000008800681],"about_ca_topic_score_codex":0.0005666475,"about_ca_topic_score_gemma":0.0008984451,"teacher_disagreement_score":0.0027936937,"about_ca_system_score_codex":0.00079082284,"about_ca_system_score_gemma":0.00056905544,"threshold_uncertainty_score":0.0093458295},"labels":[],"label_agreement":null},{"id":"W2061342795","doi":"10.2174/156800906777723976","title":"Radiation-Induced Bystander and other Non-Targeted Effects: Novel Intervention Points in Cancer Therapy?","year":2006,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Effects of Radiation Exposure","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canada Research Chairs; Irish Research Council; Science Foundation Ireland; Technological University Dublin; National Science Foundation","keywords":"Bystander effect; DNA damage; Radiation therapy; Cancer research; Cancer; Cancer cell; Medicine; Apoptosis; Biology; Immunology; DNA; Genetics; Internal medicine","score_opus":0.04054962463183979,"score_gpt":0.38925589363662094,"score_spread":0.34870626900478113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061342795","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014050335,0.9911267,0.0017518348,0.0026486095,0.00081373774,0.000016947672,0.00002369622,0.000026914557,0.0021865445],"genre_scores_gemma":[0.009846244,0.98379296,0.0010779969,0.0013050636,0.0012720987,0.000033670585,0.000039228864,0.000009506894,0.002623187],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997571,0.000056233595,0.00001803883,0.000062028616,0.000057781752,0.00004885398],"domain_scores_gemma":[0.9997633,0.00009798006,0.000034094144,0.000012022715,0.00006681704,0.000025767218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007640051,0.0006721548,0.0021468818,0.0008099341,0.00031802352,0.0017538571,0.0010472235,0.002085107,0.0042621405],"category_scores_gemma":[0.00045634003,0.00031385903,0.00075909996,0.0008077672,0.0012988243,0.0035100838,0.0006207866,0.0025725462,0.0018905633],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045587268,0.00031483933,0.0005184154,0.030767523,0.0001830578,0.0014508038,0.00082284387,0.0013535591,0.05514236,0.065288715,0.024488831,0.8192132],"study_design_scores_gemma":[0.000061495804,0.0010775948,0.0015857597,0.0037584684,0.00015088497,0.0033946673,0.0006629704,0.00071809243,0.01026536,0.040762093,0.9374883,0.00007441746],"about_ca_topic_score_codex":0.0003216315,"about_ca_topic_score_gemma":0.0006593789,"teacher_disagreement_score":0.0042621405,"about_ca_system_score_codex":0.0007219322,"about_ca_system_score_gemma":0.00076815306,"threshold_uncertainty_score":0.014258325},"labels":[],"label_agreement":null},{"id":"W2065979573","doi":"10.2174/156800911795538129","title":"Redox Environment and its Meaning for Breast Cancer Cells Fate","year":2011,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Free Radicals and Antioxidants","field":"Chemistry","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Redox; Cell biology; Intracellular; Oxidative stress; Signal transduction; Biology; Biochemistry; Chemistry","score_opus":0.046470419954510955,"score_gpt":0.3082267230743886,"score_spread":0.26175630311987763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065979573","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012998078,0.9914442,0.0009505575,0.00090154476,0.00041684703,0.0000047832646,0.000029354467,0.000013151124,0.0049399165],"genre_scores_gemma":[0.013172659,0.980893,0.0007103139,0.00035423698,0.00030050977,0.000009667971,0.000044731503,0.0000043896675,0.0045103948],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999044,0.000019070334,0.000009309849,0.000019743376,0.000035380494,0.00001209662],"domain_scores_gemma":[0.99995077,0.000017630426,0.000007670057,0.000002595978,0.000016103222,0.0000052284795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020679401,0.00031029855,0.000635402,0.00053912826,0.0003120825,0.00081085274,0.000333213,0.00074324344,0.0020837372],"category_scores_gemma":[0.00018223173,0.00010478811,0.000190991,0.00046130453,0.00048762886,0.0007168053,0.00045407063,0.0008483196,0.0012059296],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012269498,0.000052513315,0.0005030331,0.0076231924,0.00005204188,0.00085818314,0.00039187967,0.00054305734,0.065122314,0.043330565,0.017525518,0.863875],"study_design_scores_gemma":[0.0000057254138,0.000075311094,0.0009964372,0.00068985287,0.00003145772,0.0020359172,0.0002168828,0.000100735866,0.010028398,0.007887513,0.9779117,0.000020034035],"about_ca_topic_score_codex":0.0005064363,"about_ca_topic_score_gemma":0.0007088546,"teacher_disagreement_score":0.0020837372,"about_ca_system_score_codex":0.0004145652,"about_ca_system_score_gemma":0.00044259636,"threshold_uncertainty_score":0.006970823},"labels":[],"label_agreement":null},{"id":"W2071527358","doi":"10.2174/156800906777441753","title":"Regulation of Multidrug Resistance by Pro-Inflammatory Cytokines","year":2006,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Multiple drug resistance; Inflammation; Proinflammatory cytokine; P-glycoprotein; Biology; Drug resistance; ATP-binding cassette transporter; Efflux; Cancer; Mechanism (biology); Cancer research; Immunology; Pharmacology; Transporter; Gene","score_opus":0.027960139299460684,"score_gpt":0.32850020099233623,"score_spread":0.30054006169287556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071527358","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041120953,0.99725634,0.00025622075,0.00021703799,0.00015842431,0.000006121175,0.000010590309,0.000009654843,0.0016745003],"genre_scores_gemma":[0.0023942068,0.99591905,0.0002964193,0.0001416942,0.00015734456,0.000010022505,0.00001673244,0.0000011544323,0.0010634781],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99986506,0.000027867056,0.000016679454,0.000022126462,0.00005518725,0.00001301949],"domain_scores_gemma":[0.9998534,0.00005154038,0.00002686678,0.0000054599213,0.000045976296,0.000016729311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028507784,0.0006192508,0.0009005119,0.0010468374,0.00022393181,0.0006918115,0.00044245337,0.000677943,0.0021422377],"category_scores_gemma":[0.00026251926,0.00015623868,0.00023849828,0.0009964164,0.00031417128,0.00067872426,0.00030187517,0.0009017195,0.0018154391],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013711989,0.00010991057,0.0004579184,0.010648684,0.00006303164,0.0007376289,0.0001283471,0.00036202138,0.020320283,0.005887198,0.015747853,0.9454],"study_design_scores_gemma":[0.00004091102,0.00020628909,0.0023324266,0.0013382296,0.00006273349,0.0033167887,0.00010759209,0.00013446703,0.0072948416,0.0028117897,0.98233354,0.000020289233],"about_ca_topic_score_codex":0.00035791507,"about_ca_topic_score_gemma":0.0006516923,"teacher_disagreement_score":0.0021422377,"about_ca_system_score_codex":0.0004130099,"about_ca_system_score_gemma":0.00050457515,"threshold_uncertainty_score":0.0071665645},"labels":[],"label_agreement":null},{"id":"W2071672251","doi":"10.2174/1568009043333005","title":"Targeting Translation for Treatment of Cancer - A Novel Role for IRES?","year":2004,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario","funders":"","keywords":"Internal ribosome entry site; Translation (biology); Untranslated region; Biology; Eukaryotic translation; Cell biology; Protein biosynthesis; Cancer cell; Cancer; Cancer research; Messenger RNA; Genetics; Gene","score_opus":0.07399969090101047,"score_gpt":0.3989401575790323,"score_spread":0.3249404666780218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071672251","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021782206,0.9968591,0.00042003,0.0007146283,0.0003876227,0.0000071702407,0.000009699522,0.000013678454,0.0013703039],"genre_scores_gemma":[0.001716378,0.9945385,0.00068062654,0.0007313438,0.00036916253,0.000013706191,0.000025209976,0.0000045730303,0.0019204291],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99986684,0.000026444653,0.0000149225325,0.000029699311,0.00004623969,0.000015820173],"domain_scores_gemma":[0.9999064,0.000036491758,0.000016545715,0.000005718117,0.00002389334,0.000010978234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047614242,0.0008665534,0.0013956818,0.0010208508,0.00022543504,0.0007802916,0.0007893577,0.0015036716,0.0027523888],"category_scores_gemma":[0.0002740959,0.00024972347,0.00041483305,0.001049738,0.0006547637,0.0017094575,0.00043170294,0.002443734,0.0035372574],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014484116,0.00011895474,0.0001412768,0.0072275354,0.00008636373,0.0005095813,0.00008248827,0.0004000093,0.014807242,0.009796253,0.028922467,0.93776304],"study_design_scores_gemma":[0.00006374592,0.00017578654,0.000524521,0.0010162051,0.000053080887,0.0027027298,0.00004176081,0.0001330372,0.002868002,0.0039170277,0.9884828,0.000021437048],"about_ca_topic_score_codex":0.00040677894,"about_ca_topic_score_gemma":0.00082404306,"teacher_disagreement_score":0.0027523888,"about_ca_system_score_codex":0.0006301272,"about_ca_system_score_gemma":0.0004697897,"threshold_uncertainty_score":0.009207666},"labels":[],"label_agreement":null},{"id":"W2098122970","doi":"10.2174/156800910791208571","title":"Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent","year":2010,"lang":"en","type":"article","venue":"Current Cancer Drug Targets","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Poly ADP ribose polymerase; Gene silencing; PARP inhibitor; Temozolomide; Cancer research; Biology; Chemistry; Molecular biology; Polymerase; Biochemistry; DNA; Glioma; Gene","score_opus":0.02492817481694091,"score_gpt":0.3460347325329664,"score_spread":0.3211065577160255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098122970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99523973,0.0013296197,0.0021898132,0.000061642204,0.00002716027,0.000024820625,0.00030136347,0.00006663903,0.00075927464],"genre_scores_gemma":[0.9947865,0.00087947963,0.0020906155,0.000035944347,0.000008414247,0.000038068993,0.00052826275,0.000016241764,0.0016164902],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9998821,0.000016558493,0.0000151119475,0.00003146598,0.00003262326,0.000022046652],"domain_scores_gemma":[0.9999137,0.000019982523,0.00002819958,0.000012049388,0.000008484954,0.000017517366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000106470994,0.00026825743,0.00028365935,0.00013333454,0.00007540595,0.00023212555,0.00017300784,0.00017852611,0.0010343288],"category_scores_gemma":[0.00007645191,0.00012083755,0.00019497426,0.00012618018,0.00019342975,0.00014049298,0.00012007726,0.00071133504,0.00023652992],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036742545,0.00001726153,0.000049130864,0.00001532484,0.00000303126,0.000011203706,0.0000068047293,0.000038432994,0.9993759,0.000020330364,0.000013635005,0.00041238818],"study_design_scores_gemma":[0.000006556647,0.00025019035,0.0011679651,0.0000014124716,0.0000076048636,0.00005590674,0.0000065050767,0.00038653775,0.99756515,0.000007743446,0.0005429592,0.0000015132554],"about_ca_topic_score_codex":0.00036960197,"about_ca_topic_score_gemma":0.00047705785,"teacher_disagreement_score":0.0010343288,"about_ca_system_score_codex":0.00017344704,"about_ca_system_score_gemma":0.00010871317,"threshold_uncertainty_score":0.0034601688},"labels":[],"label_agreement":null},{"id":"W2100388782","doi":"10.2174/156800911793743600","title":"Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)","year":2010,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Alberta Cancer Foundation","funders":"","keywords":"Gemcitabine; Medicine; Internal medicine; Oncology; Regimen; Univariate analysis; Biliary tract; Nucleoside transporter; Cancer; Gastroenterology; Multivariate analysis; Transporter","score_opus":0.0264076660779159,"score_gpt":0.33258992787752717,"score_spread":0.3061822617996113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100388782","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995158,0.00023744346,0.000041997362,0.0000200683,0.0000016548977,0.0000022956706,0.00005289891,0.0000013425756,0.00012648286],"genre_scores_gemma":[0.99969375,0.0000678613,0.000051961048,0.000008722572,0.0000032190705,0.0000025191537,0.000108976375,8.08033e-7,0.000062188876],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989164,0.000029472265,0.000013800522,0.00002432291,0.00001716964,0.000023558212],"domain_scores_gemma":[0.9995684,0.00012643091,0.00016825083,0.000017791797,0.000039293893,0.000079849466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022648576,0.00015383014,0.00023525803,0.0002884147,0.00021181606,0.00031486634,0.00011009461,0.00029427093,0.0009534259],"category_scores_gemma":[0.00085114094,0.00011082244,0.00016235684,0.0003412625,0.000155223,0.00019771424,0.00019850174,0.00028056357,0.00018287037],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036356543,0.000011319915,0.9969944,0.0000073179694,0.000015403073,0.000078823614,0.000015996404,0.000057891204,0.0012125588,0.000004834535,0.000040577317,0.0011973112],"study_design_scores_gemma":[0.0000136863355,0.00016804526,0.9974905,0.0000034975137,0.00003737679,0.00089270796,0.0000596627,0.00049302296,0.000600154,0.000024105586,0.00021504838,0.000002133018],"about_ca_topic_score_codex":0.00064386654,"about_ca_topic_score_gemma":0.0009629297,"teacher_disagreement_score":0.0009534259,"about_ca_system_score_codex":0.00021451659,"about_ca_system_score_gemma":0.00014381322,"threshold_uncertainty_score":0.0031895638},"labels":[],"label_agreement":null},{"id":"W2107103889","doi":"10.2174/156800909789760393","title":"Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy","year":2009,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Comprehensive Cancer Network","keywords":"Multiple myeloma; Medicine; Bone disease; Disease; Current (fluid); Intensive care medicine; Bioinformatics; Osteoporosis; Internal medicine; Biology; Engineering","score_opus":0.16611818676336448,"score_gpt":0.37562812197963663,"score_spread":0.20950993521627215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107103889","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008538016,0.9963229,0.00027505125,0.0015265595,0.00040354748,0.0000042422384,0.0000068998675,0.000011275315,0.0013641526],"genre_scores_gemma":[0.0005438125,0.9967308,0.0004456259,0.00083680975,0.00038000653,0.0000069245693,0.00001423561,0.0000019925476,0.0010398957],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999723,0.000057511945,0.000033691274,0.0000368955,0.00012840539,0.000020434596],"domain_scores_gemma":[0.9995635,0.0002021524,0.000047782345,0.000016199612,0.00012058668,0.000049755294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093399565,0.0008266459,0.0014574364,0.0018321964,0.00044863773,0.0013451484,0.0012108518,0.0017845724,0.0042275125],"category_scores_gemma":[0.00082317856,0.00024996357,0.00036110796,0.0020188112,0.0010179383,0.002660299,0.0008275794,0.0029663933,0.0038022306],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006669449,0.000107003,0.000102104736,0.006818287,0.000050718467,0.0002780828,0.000090341324,0.0004438117,0.0015128466,0.00883279,0.051416382,0.930281],"study_design_scores_gemma":[0.000017220524,0.00006130457,0.00026170924,0.0017381095,0.000028930182,0.0008656546,0.000100235084,0.000094051764,0.00025451073,0.004461315,0.9921057,0.000011174276],"about_ca_topic_score_codex":0.0012769811,"about_ca_topic_score_gemma":0.0029960263,"teacher_disagreement_score":0.0042275125,"about_ca_system_score_codex":0.0010275925,"about_ca_system_score_gemma":0.0011504177,"threshold_uncertainty_score":0.014142454},"labels":[],"label_agreement":null},{"id":"W2111967651","doi":"10.2174/156800905774574011","title":"Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications","year":2005,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Cancer research; Biology; DNA methylation; Prostate cancer; Epigenetics; Gene silencing; Cancer; Urokinase receptor; Metastasis; Breast cancer; Tumor progression; Gene; Plasminogen activator; Gene expression; Endocrinology; Genetics","score_opus":0.03075453478558431,"score_gpt":0.35268053598754184,"score_spread":0.3219260012019575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111967651","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041735687,0.9979353,0.00030487493,0.0003395925,0.00010072969,0.0000027673927,0.000019077937,0.000010442588,0.0008699245],"genre_scores_gemma":[0.0032950619,0.99474984,0.00048402336,0.00021041345,0.00017407609,0.0000061605133,0.000035901776,0.0000021881517,0.0010423136],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99988437,0.000025058398,0.000012769572,0.000028712202,0.000040084316,0.000009074139],"domain_scores_gemma":[0.9998646,0.00005772308,0.00002130085,0.000004455475,0.00004134952,0.0000105360405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039675445,0.00044578427,0.00092363503,0.00085664884,0.00015441593,0.00039556218,0.00052822434,0.0006968832,0.0015195134],"category_scores_gemma":[0.0004042107,0.00014935042,0.00021008171,0.0013107393,0.00025550288,0.00043581417,0.00022097476,0.0007497261,0.0013275342],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079956015,0.000026841153,0.0007741363,0.003920166,0.000067841094,0.0004885407,0.00004435291,0.00036982953,0.004520161,0.0011837949,0.014760087,0.97376424],"study_design_scores_gemma":[0.000036901427,0.00022031962,0.008823183,0.0017570328,0.0002684855,0.012610224,0.00013030706,0.0003792924,0.0045189084,0.0027286625,0.9684912,0.000035476758],"about_ca_topic_score_codex":0.0009460796,"about_ca_topic_score_gemma":0.001681389,"teacher_disagreement_score":0.0015195134,"about_ca_system_score_codex":0.00048814694,"about_ca_system_score_gemma":0.00042731847,"threshold_uncertainty_score":0.005083263},"labels":[],"label_agreement":null},{"id":"W2112773270","doi":"10.2174/156800912801784857","title":"Inhibition of Protein N-Myristoylation: A Therapeutic Protocol in Developing Anticancer Agents","year":2012,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"14-3-3 protein interactions","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Canadian Institutes of Health Research","keywords":"Myristoylation; Biology; Kinase; Cancer; Cancer research; Carcinogenesis; Cancer cell; Pharmacology; Biochemistry; Phosphorylation","score_opus":0.08981349512724712,"score_gpt":0.418618193008455,"score_spread":0.32880469788120786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112773270","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06789652,0.83739245,0.05776074,0.0032103818,0.0011879897,0.00045278715,0.0003914318,0.00034361053,0.031364128],"genre_scores_gemma":[0.2384027,0.7085792,0.028030459,0.0018881147,0.0004321729,0.00042414715,0.0005356264,0.000046409074,0.021661272],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99990475,0.00001759181,0.0000088818715,0.000024416891,0.000030163634,0.000014102924],"domain_scores_gemma":[0.99996793,0.0000070951855,0.000007669033,0.0000030540816,0.0000093291765,0.0000049795717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023376153,0.00043883736,0.00036627063,0.00057534693,0.00020438,0.00030964336,0.00040711917,0.00065090676,0.0013867267],"category_scores_gemma":[0.000099824116,0.00020908673,0.00032441047,0.00042868385,0.0003171884,0.00073080556,0.00037458932,0.001250394,0.00085475517],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001879747,0.00018998908,0.00018073471,0.0039589554,0.00004387881,0.00044520924,0.0000969608,0.0010909791,0.8076771,0.011219303,0.003227334,0.17168151],"study_design_scores_gemma":[0.00005869785,0.0012399451,0.0011372544,0.0003237196,0.000086938955,0.0019015193,0.00004479179,0.0010338539,0.5293572,0.0020060653,0.46277264,0.000037342696],"about_ca_topic_score_codex":0.00028307093,"about_ca_topic_score_gemma":0.00060527126,"teacher_disagreement_score":0.0013867267,"about_ca_system_score_codex":0.0004547676,"about_ca_system_score_gemma":0.00030448672,"threshold_uncertainty_score":0.004639089},"labels":[],"label_agreement":null},{"id":"W2117191309","doi":"10.2174/156800911794519743","title":"Green Tea Polyphenols as Proteasome Inhibitors: Implication in Chemoprevention","year":2011,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Tea Polyphenols and Effects","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; National Institutes of Health","keywords":"Proteasome; Prodrug; Pharmacology; Bioavailability; Chemistry; Cancer research; Cancer cell; Apoptosis; Proteasome inhibitor; Cancer; Biochemistry; Biology; Medicine; Internal medicine","score_opus":0.05090194228805152,"score_gpt":0.3776791703544945,"score_spread":0.326777228066443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117191309","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002520966,0.9987722,0.00011900526,0.00015465535,0.0000865274,0.0000036902989,0.000011621718,0.000007845101,0.00059229595],"genre_scores_gemma":[0.0012022797,0.99782735,0.00018758659,0.00009736469,0.00007851681,0.0000049590276,0.000017634342,0.0000013328597,0.0005828273],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99989617,0.000017761566,0.000013026267,0.00001925666,0.000037591304,0.000016310652],"domain_scores_gemma":[0.99987197,0.000045712462,0.000022427803,0.000005234523,0.000036325437,0.000018314435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037708983,0.0008686557,0.0012777828,0.0019383085,0.0002463707,0.00073920796,0.0007226311,0.0009372722,0.0029498432],"category_scores_gemma":[0.00029504797,0.00028182092,0.00048079604,0.0021459258,0.00043025392,0.001083628,0.0004786818,0.0013663216,0.0018395459],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016557168,0.00018450255,0.00021656054,0.011791088,0.00010339425,0.00039726173,0.000058891655,0.0006315776,0.0067536007,0.0026662233,0.017435323,0.95959616],"study_design_scores_gemma":[0.000055982953,0.00021075385,0.0014697808,0.0018902052,0.00014036796,0.0014602648,0.00006547742,0.00018770057,0.0024355615,0.0022018587,0.9898582,0.000023779778],"about_ca_topic_score_codex":0.00096329226,"about_ca_topic_score_gemma":0.0024672037,"teacher_disagreement_score":0.0029498432,"about_ca_system_score_codex":0.00062132796,"about_ca_system_score_gemma":0.0005650818,"threshold_uncertainty_score":0.009868205},"labels":[],"label_agreement":null},{"id":"W2121862563","doi":"10.2174/1568009615666150105115047","title":"Nano-pharmaceutical Formulations for Targeted Drug Delivery against HER2 in Breast Cancer","year":2015,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Health Authority","funders":"","keywords":"Drug delivery; Breast cancer; Monoclonal antibody; Nanotechnology; Targeted drug delivery; Nanomedicine; Drug; Cancer; Dendrimer; Liposome; Cancer therapy; Flexibility (engineering); Medicine; Pharmacology; Nanoparticle; Chemistry; Materials science; Antibody; Immunology; Internal medicine","score_opus":0.06493306173260915,"score_gpt":0.3781428014225207,"score_spread":0.31320973968991156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121862563","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010415383,0.9952756,0.00082977756,0.0001282393,0.00013624731,0.000027254244,0.000026330103,0.000016540516,0.002518498],"genre_scores_gemma":[0.00554071,0.99024874,0.0013169348,0.00016517534,0.00008455936,0.000036039593,0.00005198454,0.000004843069,0.0025510439],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998671,0.000019253197,0.000012014564,0.00002023769,0.00006540056,0.00001597797],"domain_scores_gemma":[0.9999416,0.000019743038,0.000015445172,0.000002585814,0.0000145683525,0.0000059860745],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036052955,0.0007021858,0.0008138403,0.0022534614,0.00025948585,0.00047377462,0.00046498587,0.00080044963,0.002407362],"category_scores_gemma":[0.00021021334,0.00028813272,0.00047183756,0.0012093995,0.0002821029,0.0007465873,0.0005088125,0.0011687763,0.0018080669],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063477375,0.00022480637,0.0001467524,0.01647111,0.00008422822,0.00041319645,0.00009654962,0.0007581104,0.043645684,0.008346439,0.01430212,0.91544753],"study_design_scores_gemma":[0.00003116029,0.0002749148,0.0008989947,0.0019365329,0.000090165464,0.00218921,0.0000512762,0.00041699247,0.013943742,0.0019459949,0.97819304,0.000027930493],"about_ca_topic_score_codex":0.0005433115,"about_ca_topic_score_gemma":0.0011022823,"teacher_disagreement_score":0.002407362,"about_ca_system_score_codex":0.0004395663,"about_ca_system_score_gemma":0.00042310017,"threshold_uncertainty_score":0},"labels":[],"label_agreement":null},{"id":"W2135938421","doi":"10.2174/156800911796798922","title":"Targeting Epigenetics through Histone Deacetylase Inhibitors in Acute Lymphoblastic Leukemia","year":2011,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Epigenetics; Vorinostat; Histone deacetylase; Cancer research; Biology; Epigenetic therapy; Histone; Carcinogenesis; Leukemia; DNA methylation; Immunology; Cancer; Genetics; Gene expression; Gene","score_opus":0.03725352666084189,"score_gpt":0.36580973487302637,"score_spread":0.32855620821218445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135938421","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034506907,0.9975431,0.00022910962,0.00021803036,0.00021106548,0.000009910423,0.000020640031,0.000014991689,0.0014080582],"genre_scores_gemma":[0.0010288788,0.99733114,0.00028690483,0.0001865016,0.00011678342,0.000010696101,0.00004083326,0.0000020648765,0.0009961623],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99987686,0.000017822986,0.00001681509,0.000021289252,0.00005511784,0.000012150581],"domain_scores_gemma":[0.9998753,0.000046368674,0.000022915576,0.0000039302863,0.00003628526,0.000015296133],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039525345,0.0007335491,0.0010993974,0.0015838946,0.0002171157,0.00054016657,0.00076794456,0.00078283314,0.002088331],"category_scores_gemma":[0.00036240104,0.0002646559,0.00038040947,0.0018250393,0.00029808204,0.00089396,0.0004086681,0.0016016505,0.0020602823],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012842407,0.000102549064,0.00014902101,0.0071579833,0.0000804979,0.0002831573,0.000041241812,0.00042601136,0.004346085,0.002421101,0.024709307,0.9601548],"study_design_scores_gemma":[0.00006554463,0.00023627694,0.00092723395,0.0010198733,0.00010960353,0.0019024182,0.000035778372,0.00015969027,0.0017935123,0.0011703351,0.9925605,0.000019266668],"about_ca_topic_score_codex":0.0008338443,"about_ca_topic_score_gemma":0.0021258055,"teacher_disagreement_score":0.002088331,"about_ca_system_score_codex":0.0005849074,"about_ca_system_score_gemma":0.0005128278,"threshold_uncertainty_score":0.006986201},"labels":[],"label_agreement":null},{"id":"W2149276366","doi":"10.2174/156800906778194586","title":"Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers","year":2006,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Drug; Medicine; Intensive care medicine; Drug development; Pharmacology; Oncology","score_opus":0.05245195177791379,"score_gpt":0.39711500387024956,"score_spread":0.3446630520923358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149276366","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004099397,0.99691784,0.0005272409,0.00019329072,0.00016264498,0.000023612705,0.000028932549,0.000016157352,0.0017203195],"genre_scores_gemma":[0.0014506439,0.9970464,0.0005907886,0.00015115933,0.000081882856,0.000022563081,0.000035423694,0.0000025412119,0.00061865395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99976414,0.000040401897,0.000030013432,0.000038637005,0.00010369729,0.000023043238],"domain_scores_gemma":[0.99976844,0.00009887823,0.000043693803,0.00000811323,0.00006283453,0.000018065995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072709634,0.00087130547,0.0013186906,0.0022814958,0.00022646633,0.0010085593,0.0009689235,0.0009889845,0.0021706696],"category_scores_gemma":[0.000602618,0.00040636654,0.00053818844,0.0017126618,0.00052848697,0.0012427109,0.00052038435,0.001624684,0.001448854],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000090949114,0.00014433678,0.00015699005,0.015958391,0.00008839824,0.00024942085,0.00006208487,0.0009597474,0.007084557,0.0059136697,0.012148438,0.957143],"study_design_scores_gemma":[0.000034082626,0.0002789823,0.00065410626,0.0018937574,0.00009813985,0.0011485261,0.000043261647,0.00022312882,0.0026822677,0.0017539607,0.99116665,0.00002317507],"about_ca_topic_score_codex":0.000713146,"about_ca_topic_score_gemma":0.0013320296,"teacher_disagreement_score":0.0022814958,"about_ca_system_score_codex":0.00062561943,"about_ca_system_score_gemma":0.0008989649,"threshold_uncertainty_score":0.007261634},"labels":[],"label_agreement":null},{"id":"W2164239756","doi":"10.2174/156800912802429292","title":"Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma","year":2012,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Stromal cell; Multiple myeloma; Syngenic; In vivo; Cancer research; Bone marrow; Tumor microenvironment; Medicine; Biology; Immunology; Tumor cells","score_opus":0.32725508467932346,"score_gpt":0.44190329542170326,"score_spread":0.1146482107423798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164239756","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006429368,0.99467033,0.0014620328,0.00031055367,0.00019452309,0.000028928032,0.00005340297,0.00003371837,0.0026036063],"genre_scores_gemma":[0.0024553423,0.9943427,0.001712508,0.00024625802,0.00012019755,0.00004018089,0.00008830693,0.0000054762004,0.000989059],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997577,0.00006000184,0.00003245719,0.00003275489,0.00009974357,0.000017347948],"domain_scores_gemma":[0.99971217,0.00013696276,0.000052834726,0.00001651049,0.00005810595,0.000023378509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000909965,0.00077226956,0.0012300654,0.0020219407,0.00016845748,0.0007908481,0.0008158673,0.0010247788,0.0020670197],"category_scores_gemma":[0.00034678582,0.0002967188,0.00046198774,0.0013098195,0.0006783702,0.0010531894,0.00047692054,0.00232631,0.0014078432],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018180948,0.00031241294,0.00023672503,0.014546138,0.00009030753,0.00041720283,0.00008056683,0.00057842967,0.0528964,0.012772817,0.01726282,0.9006243],"study_design_scores_gemma":[0.000045306206,0.00043465575,0.0010027613,0.0016132264,0.00013117027,0.0019984401,0.000048411977,0.00018080533,0.010728792,0.0024404277,0.9813461,0.000029843764],"about_ca_topic_score_codex":0.00048042386,"about_ca_topic_score_gemma":0.0007966495,"teacher_disagreement_score":0.0020670197,"about_ca_system_score_codex":0.0005216701,"about_ca_system_score_gemma":0.000568825,"threshold_uncertainty_score":0.0069149137},"labels":[],"label_agreement":null},{"id":"W2327659954","doi":"10.2174/156800911794519770","title":"Clioquinol – A Novel Copper-Dependent and Independent Proteasome Inhibitor","year":2011,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Biological Research and Disease Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Clioquinol; Proteasome inhibitor; Proteasome; Pharmacology; Chemistry; Extracellular; Intracellular; Mechanism of action; Prodrug; Cancer research; Biochemistry; Medicine; In vitro","score_opus":0.07753226772495421,"score_gpt":0.3724427619954073,"score_spread":0.2949104942704531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327659954","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013848329,0.9941478,0.0008850531,0.00023067783,0.0001901504,0.00001760133,0.000033968114,0.000037855414,0.0030720416],"genre_scores_gemma":[0.010179962,0.9836061,0.0011122233,0.00033349075,0.00014839688,0.000028598695,0.00013394131,0.000005125694,0.0044520744],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99992144,0.000009380496,0.000008201063,0.000016557438,0.00003327692,0.000011084379],"domain_scores_gemma":[0.999966,0.000008015661,0.0000072879984,0.0000014061128,0.000012558138,0.0000047987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016269964,0.0004988211,0.00060231023,0.001062689,0.00016821158,0.00033019332,0.0005889387,0.0004773283,0.0012231872],"category_scores_gemma":[0.00012189217,0.0001852132,0.00025692536,0.0006795012,0.00022179374,0.00049327454,0.00023952236,0.0009081444,0.0011359595],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013060695,0.00018518203,0.00016131299,0.0081071695,0.00008025684,0.00055250956,0.00005386736,0.00074623985,0.0507702,0.0045097205,0.023274926,0.9114281],"study_design_scores_gemma":[0.000055347333,0.00027441737,0.00082781725,0.0005037234,0.000053589356,0.00268326,0.000021918964,0.00025313566,0.013742858,0.0009901932,0.98057014,0.000023490806],"about_ca_topic_score_codex":0.00066547585,"about_ca_topic_score_gemma":0.0017056918,"teacher_disagreement_score":0.0012231872,"about_ca_system_score_codex":0.00047044712,"about_ca_system_score_gemma":0.0003142977,"threshold_uncertainty_score":0.0040919185},"labels":[],"label_agreement":null},{"id":"W2422973035","doi":"10.2174/1568009615666150616123548","title":"Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous","year":2015,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Drug delivery; Medicine; Blood–brain barrier; Glioblastoma; Chemotherapy; Radiation therapy; Brain tumor; Central nervous system; Surgery; Pathology; Internal medicine; Cancer research","score_opus":0.055808800274475975,"score_gpt":0.3625731993795175,"score_spread":0.3067643991050415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2422973035","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00038035406,0.99685955,0.00031616288,0.00021731795,0.00014593224,0.0000072740313,0.000014303031,0.000009603443,0.0020494245],"genre_scores_gemma":[0.0017866401,0.9967608,0.0002684681,0.00014766767,0.000083577484,0.000007945045,0.000019823623,0.0000020058528,0.0009230524],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998697,0.000020682253,0.000017370023,0.000028662591,0.000049225557,0.00001424623],"domain_scores_gemma":[0.9998778,0.00005486223,0.000022509683,0.0000050391127,0.000031043754,0.000008728122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024695983,0.00068890967,0.0010000565,0.0014407996,0.0002620611,0.0007276564,0.00057892076,0.0007995562,0.0026935055],"category_scores_gemma":[0.0003424694,0.00023924118,0.00042446604,0.0011885919,0.00040211226,0.0010252891,0.0004495322,0.0012431317,0.0015474247],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006324449,0.00008206604,0.00017739322,0.023055904,0.000082149905,0.00036507015,0.00012212212,0.0004693274,0.010465023,0.0061478256,0.017303925,0.9416658],"study_design_scores_gemma":[0.000014112336,0.00014124933,0.00070975604,0.0023133883,0.000105636616,0.0023860948,0.000060718492,0.00016967306,0.003516928,0.0014263705,0.9891377,0.000018305003],"about_ca_topic_score_codex":0.0010684711,"about_ca_topic_score_gemma":0.0018560173,"teacher_disagreement_score":0.0026935055,"about_ca_system_score_codex":0.00055086776,"about_ca_system_score_gemma":0.0006749073,"threshold_uncertainty_score":0.009010673},"labels":[],"label_agreement":null},{"id":"W2786620549","doi":"10.2174/1568009617666170206111609","title":"Oncolytic Viruses: The Best is Yet to Come","year":2018,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Canadian Institutes of Health Research","keywords":"Oncolytic virus; Virotherapy; Tumor microenvironment; Medicine; Immune system; Immune modulation; Immunology","score_opus":0.09197668856040245,"score_gpt":0.4374924473297759,"score_spread":0.34551575876937346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2786620549","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031852178,0.99314684,0.00069945736,0.0033894717,0.00084361044,0.0000059308722,0.000026738287,0.000027065751,0.0015422779],"genre_scores_gemma":[0.0019080266,0.99416083,0.00075284136,0.0011152488,0.0006216735,0.00000805912,0.00004375452,0.0000076998185,0.0013818787],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99961686,0.000074619835,0.000044202487,0.00006945252,0.0001480706,0.0000467446],"domain_scores_gemma":[0.9988073,0.0006686896,0.000092519935,0.00005391059,0.0002524235,0.00012521015],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015716517,0.00070082734,0.0013163578,0.000947281,0.0005579737,0.003261409,0.0008627578,0.0021539703,0.0042879903],"category_scores_gemma":[0.0018975539,0.00033601644,0.0004616567,0.0009987364,0.0013156446,0.0064400733,0.0013072299,0.0032661217,0.0027917908],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000093817405,0.00009259539,0.00023550677,0.009513637,0.000053965927,0.0002348608,0.00021873946,0.00037356175,0.005396333,0.023676364,0.03645669,0.9236539],"study_design_scores_gemma":[0.000007357447,0.00008731491,0.00012390179,0.0015851506,0.000029664145,0.00066498574,0.00013184146,0.00008125111,0.0013145257,0.0062645357,0.9896909,0.000018650011],"about_ca_topic_score_codex":0.00066870044,"about_ca_topic_score_gemma":0.0013907102,"teacher_disagreement_score":0.0042879903,"about_ca_system_score_codex":0.0006951718,"about_ca_system_score_gemma":0.0016440573,"threshold_uncertainty_score":0.014344752},"labels":[],"label_agreement":null},{"id":"W2922582842","doi":"10.2174/1568009619666190326120833","title":"Inhibition of PI3K/mTOR Pathways with GDC-0980 in Pediatric Leukemia: Impact on Abnormal FLT-3 Activity and Cooperation with Intracellular Signaling Targets","year":2019,"lang":"en","type":"article","venue":"Current Cancer Drug Targets","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"PI3K/AKT/mTOR pathway; Protein kinase B; Leukemia; Phosphorylation; Pharmacology; Kinase; IC50; Cancer research; Chemistry; Apoptosis; Medicine; In vitro; Internal medicine; Biochemistry","score_opus":0.008210147615025337,"score_gpt":0.24383970911800662,"score_spread":0.23562956150298128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922582842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945693,0.0032280113,0.00055309566,0.00010125529,0.00001895408,0.00004850856,0.00039531395,0.00005707121,0.0010285082],"genre_scores_gemma":[0.994875,0.0022217666,0.001297851,0.000054246826,0.000009834468,0.00005819569,0.00087935955,0.00001123004,0.0005925423],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99992025,0.000013082679,0.000009098,0.000012075994,0.000019384814,0.000026155365],"domain_scores_gemma":[0.9999603,0.00000796295,0.000010106272,0.0000042837196,0.000005447699,0.000011851338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015103747,0.00032373946,0.00037698704,0.00022471143,0.00010482559,0.00019688404,0.0002630559,0.00016619686,0.0010586072],"category_scores_gemma":[0.00011339224,0.00007641962,0.00017339726,0.00022030031,0.00016104765,0.00012324382,0.00015265214,0.00058992277,0.00021593872],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018514125,0.0006460209,0.0033725812,0.000287676,0.00004605415,0.0002335731,0.00003536109,0.0008805231,0.960985,0.00028137935,0.0005508518,0.030829653],"study_design_scores_gemma":[0.00045745083,0.005388623,0.01647159,0.00001972767,0.00011006275,0.0011197631,0.000039251605,0.0016887462,0.96564996,0.00007086248,0.008973325,0.000010640697],"about_ca_topic_score_codex":0.0006266847,"about_ca_topic_score_gemma":0.001490923,"teacher_disagreement_score":0.0010586072,"about_ca_system_score_codex":0.0003726846,"about_ca_system_score_gemma":0.0003637735,"threshold_uncertainty_score":0.00354141},"labels":[],"label_agreement":null},{"id":"W2987452154","doi":"10.2174/1568009619666191111153049","title":"In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors","year":2019,"lang":"en","type":"article","venue":"Current Cancer Drug Targets","topic":"Chromatin Remodeling and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Receptor tyrosine kinase; Insulin-like growth factor 1 receptor; Cancer research; Biology; Receptor; Growth factor receptor; Growth factor; Genetics","score_opus":0.005075892739689982,"score_gpt":0.23635760263322517,"score_spread":0.2312817098935352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987452154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792921,0.011065519,0.0035468466,0.00020302607,0.00009503035,0.00008440776,0.0016525016,0.0001306641,0.0039298614],"genre_scores_gemma":[0.9888905,0.0032199717,0.0040203896,0.000076160744,0.00001741797,0.0000622903,0.0016177953,0.000016412898,0.002078962],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99983454,0.00002240437,0.000013878697,0.000032357133,0.00006396133,0.00003278429],"domain_scores_gemma":[0.9999193,0.000025024812,0.000015301226,0.000007993103,0.000017802813,0.000014612777],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021122495,0.00028606888,0.00030397213,0.00022442023,0.00013848551,0.00024330891,0.00017742814,0.00017555649,0.0018397884],"category_scores_gemma":[0.00015576283,0.00008986407,0.00032041647,0.00018596333,0.00008028498,0.00012948271,0.00012640272,0.00044113118,0.00048230166],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035501385,0.00020474225,0.0017397524,0.00022177302,0.00003937174,0.00016320674,0.00003126485,0.0009771438,0.98557913,0.00010956899,0.0005089451,0.010069947],"study_design_scores_gemma":[0.000045078406,0.0019312232,0.00928438,0.000019624007,0.000103803366,0.00066220167,0.00005999284,0.0031018641,0.97725403,0.00004429104,0.0074831787,0.000010294759],"about_ca_topic_score_codex":0.0016307473,"about_ca_topic_score_gemma":0.0032310067,"teacher_disagreement_score":0.0018397884,"about_ca_system_score_codex":0.00035975428,"about_ca_system_score_gemma":0.00027901534,"threshold_uncertainty_score":0.006154716},"labels":[],"label_agreement":null},{"id":"W3159431400","doi":"10.2174/1568009621666210504085527","title":"Cytotoxicity and Target Modulation in Pediatric Solid Tumors by the Proteasome Inhibitor Carfilzomib","year":2021,"lang":"en","type":"article","venue":"Current Cancer Drug Targets","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Carfilzomib; Proteasome inhibitor; Rhabdomyosarcoma; Cancer research; Pediatric cancer; Cytotoxic T cell; Medicine; Cisplatin; Cytotoxicity; Proteasome; Pharmacology; Cancer; Chemotherapy; In vitro; Multiple myeloma; Sarcoma; Chemistry; Immunology; Internal medicine; Pathology","score_opus":0.012103346587631111,"score_gpt":0.26819470091373687,"score_spread":0.25609135432610575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159431400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880584,0.009347109,0.001109356,0.000091196656,0.000014020142,0.000044510813,0.00037191968,0.000054545515,0.0009090092],"genre_scores_gemma":[0.9934894,0.0045566815,0.0009054103,0.000025844618,0.000011342091,0.000034866436,0.0006716814,0.000007524606,0.00029730285],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9999033,0.000017126762,0.000007874289,0.00001348998,0.00003227688,0.00002583764],"domain_scores_gemma":[0.9999255,0.00001784894,0.000026777421,0.000006061202,0.000011340967,0.0000123865075],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014117584,0.0002674099,0.00030938987,0.00021840986,0.00011098932,0.00021647655,0.00013837582,0.00014116373,0.000569216],"category_scores_gemma":[0.00014827201,0.00006809688,0.00017981374,0.00022458997,0.00011391516,0.00011165927,0.000089839225,0.00036191594,0.00013249603],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011117981,0.00028543535,0.007245777,0.0002817671,0.000047136535,0.00035134776,0.000040125495,0.0019249421,0.9518385,0.000120595214,0.00052718143,0.036225528],"study_design_scores_gemma":[0.00012642499,0.005384661,0.047701035,0.000018614923,0.00008960028,0.0021664584,0.000043690434,0.0022989376,0.9360749,0.000059430542,0.006028691,0.0000075922085],"about_ca_topic_score_codex":0.0011393657,"about_ca_topic_score_gemma":0.0021752238,"teacher_disagreement_score":0.0011393657,"about_ca_system_score_codex":0.0004508671,"about_ca_system_score_gemma":0.00032083833,"threshold_uncertainty_score":0.0032712817},"labels":[],"label_agreement":null},{"id":"W4206024180","doi":"10.2174/1568009622666211231140623","title":"The Potential of Natural Products in the Treatment of Triple-negative Breast Cancer","year":2021,"lang":"en","type":"article","venue":"Current Cancer Drug Targets","topic":"Curcumin's Biomedical Applications","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Institute of Infection and Immunity; University of Ottawa","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Triple-negative breast cancer; Natural (archaeology); Breast cancer; Medicine; Cancer; Internal medicine; Biology","score_opus":0.010211364303566737,"score_gpt":0.2927029449318295,"score_spread":0.2824915806282628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206024180","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0067839604,0.9880504,0.00058948697,0.00054535066,0.0002680231,0.000026109188,0.00015527885,0.000024181458,0.0035572776],"genre_scores_gemma":[0.046649944,0.94811195,0.0016614429,0.0006701556,0.00028040662,0.000030618252,0.0003267408,0.000008779256,0.0022599234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9999088,0.000023590947,0.000011740744,0.000013747779,0.00003175496,0.000010436262],"domain_scores_gemma":[0.9998847,0.00003994112,0.000026434715,0.000004601605,0.000032351414,0.0000119410515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026506573,0.00032391417,0.00049280364,0.0012935387,0.00015040798,0.00048408547,0.00020681629,0.00037991695,0.0017713829],"category_scores_gemma":[0.0003216557,0.00008998756,0.0004516446,0.0006136096,0.00015004085,0.0004206877,0.00027848914,0.0007696335,0.000634046],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062828953,0.00037688314,0.00073027017,0.015956098,0.00023234612,0.00090802246,0.00010494246,0.0005133998,0.048989374,0.0031508105,0.0095902495,0.9188194],"study_design_scores_gemma":[0.00018124885,0.0026216558,0.009618263,0.0043158857,0.0006806241,0.0045034518,0.00022843057,0.0004479757,0.028097207,0.0035722842,0.94566303,0.00006991458],"about_ca_topic_score_codex":0.00030706023,"about_ca_topic_score_gemma":0.0008111185,"teacher_disagreement_score":0.0017713829,"about_ca_system_score_codex":0.00019013973,"about_ca_system_score_gemma":0.00025876964,"threshold_uncertainty_score":0.005925894},"labels":[],"label_agreement":null},{"id":"W4220827996","doi":"10.2174/1568009622666220317091723","title":"Current Treatment and Future Trends of Immunotherapy in BreastCancer","year":2022,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Immunotherapy; Medicine; Breast cancer; Clinical trial; Metastatic breast cancer; Oncology; Cancer; Immune checkpoint; Disease; Cancer immunotherapy; Blockade; Internal medicine","score_opus":0.04692936036399204,"score_gpt":0.3792937953587975,"score_spread":0.33236443499480545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220827996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000058366233,0.99869883,0.00008633436,0.00042001458,0.00017620422,0.000004270782,0.000011636157,0.0000054923235,0.0005388507],"genre_scores_gemma":[0.00036338787,0.998629,0.00015810378,0.00035755057,0.00016944855,0.000006962386,0.000022991495,0.0000012753022,0.00029140143],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996617,0.000080844184,0.000049720238,0.000049195183,0.00012167265,0.00003690531],"domain_scores_gemma":[0.9993709,0.00035194238,0.000073087984,0.000015739508,0.00014482936,0.000043588712],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011915257,0.000738715,0.0012347708,0.0019397046,0.00025987407,0.0012438732,0.00091749744,0.001295718,0.0041087703],"category_scores_gemma":[0.001178672,0.000299217,0.0006065455,0.0019526939,0.0005060211,0.0018160484,0.0007183566,0.0024739925,0.002123634],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010203014,0.00007004669,0.00013355236,0.016281532,0.000065974826,0.00009874692,0.000045356504,0.00039665768,0.0010080079,0.0039529097,0.026780453,0.95106477],"study_design_scores_gemma":[0.000030181753,0.00014263087,0.00057372864,0.0059455014,0.00009779868,0.00065855053,0.000050910756,0.00013527066,0.0002826899,0.00323807,0.9888284,0.000016259599],"about_ca_topic_score_codex":0.00080662296,"about_ca_topic_score_gemma":0.0017192658,"teacher_disagreement_score":0.0041087703,"about_ca_system_score_codex":0.00085725635,"about_ca_system_score_gemma":0.0014023567,"threshold_uncertainty_score":0.013745189},"labels":[],"label_agreement":null}]}